Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Johnson & Johnson's ₹100 Crore Drink Blocked! Court Delivers Shocking Verdict on ORSL

Consumer Products

|

Updated on 12 Nov 2025, 12:06 pm

Whalesbook Logo

Reviewed By

Satyam Jha | Whalesbook News Team

Short Description:

The Delhi High Court has refused to grant interim relief to JNTL Consumer Health, the Indian subsidiary of Johnson & Johnson, allowing them to sell their ORSL Electrolyte Drink. The ban, stemming from FSSAI directives against misleading ORS labels, affects nearly ₹100 crore worth of unsold stock. The court expressed concerns that consumers suffering from diarrhea might be misled.
Johnson & Johnson's ₹100 Crore Drink Blocked! Court Delivers Shocking Verdict on ORSL

▶

Detailed Coverage:

The Delhi High Court, through a Division Bench comprising Chief Justice Devendra Kumar Upadhyaya and Justice Tushar Rao Gedela, has denied an interim order that would have permitted JNTL Consumer Health, Johnson & Johnson's Indian arm, to sell its ORSL Electrolyte Drink. This decision follows a directive from the Food Safety and Standards Authority of India (FSSAI) that bans beverages with misleading Oral Rehydration Solution (ORS) labels. The company has approximately ₹100 crores worth of ORSL stock currently unsold.

The court expressed concern that individuals suffering from diarrhea, who typically seek ORS to rebalance electrolytes, might be misled into purchasing JNTL's product, which is advertised as an 'energy drink with electrolytes'. This ruling comes after a single-judge bench also refused to interfere with the FSSAI orders, which were initially challenged by Dr. Reddy's Laboratories.

JNTL Consumer Health had filed a plea challenging the FSSAI's directives issued on October 14, 15, and 30, along with Regulation 5 of the Food Safety and Standards (Food Recall Procedure) Regulations, 2017. Their senior counsels argued that the product has been in the market for over two decades without any complaints of adulteration, and they have already ceased manufacturing, planning to rebrand the product. They stressed that treating the ₹100 crore stock as an adulterated drug would be unfair.

However, the court remained unconvinced by these arguments and rejected the plea for interim relief.

Impact This ruling directly impacts Johnson & Johnson's Indian operations by preventing the sale of a significant stock of their product, potentially leading to financial losses and necessitating a re-evaluation of their marketing and labeling strategies in India. It also highlights the stringent regulatory environment for health and consumer products in the country. Rating: 6/10

Difficult Terms: Interim Orders: Temporary orders issued by a court before a final judgment is made. Subsidiary: A company controlled by a holding company. Food Safety and Standards Authority of India (FSSAI): The statutory body responsible for protecting and promoting public health through regulation and supervision of food safety in India. Oral Rehydration Solution (ORS): A mixture of salts and glucose used to treat dehydration, especially that due to diarrhea. Misleading Labels: Labels that convey false or deceptive information about a product. Division Bench: A panel of two or more judges of a court. Adulterated: Lowered in quality by adding inferior or harmful substances. Regulation: A rule or directive made and maintained by an authority.


SEBI/Exchange Sector

BSE Ltd. Q2 Earnings EXPLODE Past Expectations! Is This The Next Big Stock Surge?

BSE Ltd. Q2 Earnings EXPLODE Past Expectations! Is This The Next Big Stock Surge?

SEBI's BIG Plan to Revamp Stock Lending! Are High Costs Killing This Trading Tool? 🚀

SEBI's BIG Plan to Revamp Stock Lending! Are High Costs Killing This Trading Tool? 🚀

BSE Ltd. Q2 Earnings EXPLODE Past Expectations! Is This The Next Big Stock Surge?

BSE Ltd. Q2 Earnings EXPLODE Past Expectations! Is This The Next Big Stock Surge?

SEBI's BIG Plan to Revamp Stock Lending! Are High Costs Killing This Trading Tool? 🚀

SEBI's BIG Plan to Revamp Stock Lending! Are High Costs Killing This Trading Tool? 🚀


Personal Finance Sector

Start NOW! Your ₹1 Lakh Could Become ₹93 Lakhs: The Astonishing Magic of Compounding Revealed!

Start NOW! Your ₹1 Lakh Could Become ₹93 Lakhs: The Astonishing Magic of Compounding Revealed!

Start NOW! Your ₹1 Lakh Could Become ₹93 Lakhs: The Astonishing Magic of Compounding Revealed!

Start NOW! Your ₹1 Lakh Could Become ₹93 Lakhs: The Astonishing Magic of Compounding Revealed!